Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pawsitive impact: How pet contact ameliorates adult inflammatory stress responses in individuals raised in an urban environment.

Brain, behavior, and immunity·2025
Same author

Efficacy of integrated social cognitive remediation vs neurocognitive remediation in schizophrenia: Results from the multicenter randomized controlled ISST (Integrated Social Cognition And Social Skills Therapy) study.

Schizophrenia research·2025
Same author

Sensori- and psychomotor abnormalities, psychopathological symptoms and functionality in schizophrenia-spectrum disorders: a network analytic approach.

Schizophrenia (Heidelberg, Germany)·2025
Same author

Anhedonia relates to reduced striatal reward anticipation in depression but not in schizophrenia or bipolar disorder: A transdiagnostic study.

Cognitive, affective & behavioral neuroscience·2025
Same author

Real-time mechanism-based interventions for daily alcohol challenges: Protocol for ecological momentary assessment and intervention.

Digital health·2025
Same author

Loneliness is associated with different structural brain changes in schizophrenia spectrum disorders and major depression.

Schizophrenia research·2025

Related Experiment Video

Updated: Jun 17, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Polypharmacy in schizophrenia.

Mathias Zink1, Susanne Englisch, Andreas Meyer-Lindenberg

  • 1Central Institute of Mental Health, Mannheim, Germany.

Current Opinion in Psychiatry
|January 7, 2010
PubMed
Summary
This summary is machine-generated.

Combination therapy for schizophrenia is common, especially for treatment-resistant cases. Evidence for polypharmacy is limited, necessitating more research, though some combinations show promise for specific symptoms.

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Related Experiment Videos

Last Updated: Jun 17, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Neuroscience

Background:

  • Schizophrenia treatment often involves polypharmacy despite guidelines recommending monotherapy.
  • Combined psychotropic agents are frequently used for treatment-refractory schizophrenia.
  • This review examines the evidence for combination therapies in schizophrenia management.

Purpose of the Study:

  • To review the empirical basis for combining psychotropic agents in schizophrenia.
  • To assess the clinical relevance of polypharmacy in schizophrenia treatment.
  • To summarize evidence for antipsychotic combination strategies and augmentation.

Main Methods:

  • Literature review of empirical studies on combination therapy in schizophrenia.
  • Analysis of evidence for augmenting antipsychotics with mood stabilizers, antidepressants, and experimental substances.
  • Evaluation of data on addressing treatment resistance, cognitive deficits, and side effects.

Main Results:

  • Rigorous data on combination therapy in schizophrenia are scarce.
  • Antipsychotic-antidepressant combinations show some support for negative symptoms and depression.
  • Augmentation with lithium and mood stabilizers has limited compelling evidence but may benefit subgroups.
  • Cognitive remediation is recommended for treatment-resistant cognitive symptoms over pharmacological augmentation.
  • Adding a second atypical antipsychotic may help with clozapine-resistant symptoms.

Conclusions:

  • Further randomized controlled trials, naturalistic studies, and head-to-head trials are crucial for schizophrenia combination therapy.
  • Specific combinations, like antipsychotics with antidepressants, may benefit certain symptom clusters.
  • Evidence for other augmentation strategies remains limited, highlighting the need for personalized treatment approaches.